A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Eleclazine (Primary)
- Indications Long QT syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 07 Jun 2017 Biomarkers information updated
- 24 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 08 Sep 2016 Status changed from recruiting to active, no longer recruiting.